

Chugai and Towa launch edirol tablet for osteoporosis treatment in Japan

December 12, 2022 | News

Edirol is an active vitamin D₃ derivative created by Chugai, which can improve calcium and bone metabolism



Japanese firms Chugai Pharmaceutical and Towa Pharmaceutical have announced that Towa launched Edirol Tablets 0.5 µg/0.75 µg (generic name: eldecacitol, hereafter, Edirol Tablet) for an osteoporosis treatment (an active vitamin D₃ preparation) upon the listing of the national health insurance (NHI) reimbursement price list. Edirol Tablet was approved by the Ministry of Health, Labour and Welfare (MHLW) on August 15, 2022.

While Chugai takes responsibilities as a marketing authorization holder, Towa is solely responsible for marketing and providing information on appropriate use of Edirol Tablet. Chugai manufactures Edirol Tablet and supplies to Towa. Chugai continues to market and provide information on Edirol Capsule 0.5 µg/0.75 µg (hereafter, Edirol Capsule). Towa markets an authorized generic (AG) version of Edirol Capsule.

Edirol is an active vitamin D₃ derivative created by Chugai, which can improve calcium and bone metabolism.